1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Celltrion Is Latest To File Eylea Rival In US

Korean Firm Submits Application For CT-P42 Aflibercept Biosimilar To US FDA

 
• By Dave Wallace

Celltrion has become the latest firm to reveal that it has filed a biosimilar Eylea application with the US FDA in the form of its CT-P42 aflibercept candidate.

perfect blue eye macro in a sterile environment and perfect vision in resolution 6k, concept, the vision of the future and healthy life concept. view precise and straight to the target.
Celltrion has submitted its Eylea biosimilar to the FDA • Source: Shutterstock

Celltrion has revealed a filing for a biosimilar version of Eylea (aflibercept) in the US, stating that it has filed its CT-P42 candidate with the US Food and Drug Administration to cover all indications of the original ophthalmic brand, excluding pediatric indications.

The Korean firm said it planned to “proceed sequentially” with filings in other major global markets such as Europe, noting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Byooviz US Launch Slated For 2026 As Harrow Touts Immediate Uptake Potential

 
• By Dean Rudge

Harrow is taking aim at launching new partner Samsung Bioepis’ Byooviz biosimilar to Lucentis in 2026.

Richter Sets Launch Timetable for Denosumab and Tocilizumab Biosimilars

 
• By Dean Rudge

Gedeon Richter’s management discussed timelines for two key biosimilars during the firm’s first-half earnings call, while also revealing how the firm’s General Medicines division had suffered setbacks in the three months to June 30.

Lupin Couples Up With Sandoz For Global Lucentis Biosimilar Deal

 
• By Urtė Fultinavičiūtė

Sandoz snatched commercialization rights to Lupin’s ranibizumab biosimilar across multiple global markets, while also taking steps to decarbonize its operations in Europe.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

More from Products

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 
• By Urtė Fultinavičiūtė

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

Arizonans To Be Offered Up To 80% Discount On Generic Drugs

 
• By Urtė Fultinavičiūtė

Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.